How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 10, 1999, Pages 847-850

  Comstock, G W ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Training Center for Public Health Research   (United States)

Author keywords

Chemoprevention; Isoniazid; Tuberculosis

Indexed keywords

ISONIAZID;

ADULT; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HUMAN; IMMUNOCOMPETENCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RETREATMENT; REVIEW; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; CLINICAL TRIALS; HUMANS; IMMUNOCOMPETENCE; ISONIAZID; TIME FACTORS; TUBERCULOSIS, PULMONARY;

EID: 0032827110     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. American Thoracic Society. Preventive therapy of tuberculous infection. Am Rev Respir Dis 1974; 110: 371-374.
2. American Thoracic Society/Centers for Disease Control. Treatment of tuberculosis and other mycobacterial diseases. Am Rev Respir Dis 1983; 127: 790-796.
3. American Thoracic Society/Centers for Disease Control. Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 1986; 134: 355-363.
4. American Thoracic Society/Centers for Disease Control and Prevention. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359-1374.
5. Centers for Disease Control and Prevention. Prevention and control of tuberculosis in correctional facilities: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1996; 45(RR-8): 1-27.
6. Maryland Department of Health and Mental Hygiene. Guidelines for Tuberculosis Control, 1990.
7. Blumberg H M, Bock N. Georgia TB Reference Guide. Atlanta, GA: Atlanta TB Prevention Coalition, 1995: pp 10-18.
8. Gordin F M, Matts J P, Miller C, et al., for the Terry Beirn Community Programs for Clinical Research on AIDS. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997; 337: 315-320.
9. Whalen C C, Johnson J L, Okwera A, et al., for the Uganda-Case Western Reserve University Research Collaboration. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997; 337: 801-808.
10. Halsey N A, Coberly J S, Desormeaux J, et al. Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351: 786-792.
11. Gordin F, Chaisson R, Matts J, et al. A randomized trial of 2 months of rifampin (RIF) and pyrazinamide (PZA) versus 12 months of isoniazid (INH) for the prevention of tuberculosis (TB) in HIV-positive (+), PPD+ patients. Abstract LB5. Program and Abstracts, 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
12. Hawken M P, Meme H K, Elliott L C, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997; 11: 875-882.
13. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12: 2447-2457.
14. International Union against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-564.
15. Snider D E Jr, Caras G J, Koplan J P. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA 1986; 255: 1579-1583.
16. Falk A, Fuchs G F. Prophylaxis with isoniazid in inactive tuberculosis. A Veterans Administration Cooperative Study XII. Chest 1978; 73: 44-48.
17. Comstock G W, Baum C, Snider D E Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel Isoniazid Studies. Am Rev Respir Dis 1979; 119: 827-830.
18. Katz J, Kunofsky S, Damijonaitis V, Lafleur A, Caron T. Effect of isoniazid upon the reactivation of inactive tuberculosis. Final report. Am Rev Respir Dis 1965; 91: 345-350.
19. Comstock G W, Woolpert S F. Preventive Therapy. In: Kubica G P, Wayne I, G, eds. The mycobacteria: a sourcebook. New York: Marcel Dekker, 1984: pp 1071-1082.
20. Ferebee S H. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res 1970; 17: 28-106.
21. Comstock G W, Ferebee S H, Hammes L M. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967; 95: 935-943.
22. Bishai W R, Chaisson R E. Short-course chemoprophylaxis for tuberculosis. Clin Chest Med 1997; 18: 115-122.
23. Mitchison D A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219-225.